PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Substantial Shareholding

19 Jun 2008 17:26

RNS Number : 1421X
ReGen Therapeutics PLC
19 June 2008
 
 
19th June 2008
 
REGEN THERAPEUTICS PLC
(“ReGen” or the “Company”; Ticker: (RGT))
 
 
TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES
 
 
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):
 
ReGen Therapeutics Plc
 
2. Reason for the notification:
 
An acquisition or disposal of voting rights
 
3. Full name of person(s) subject to the notification obligation (iii):
 
Andrew Clement Wilson
 
4. Full name of shareholder(s) (if difference from 3):
 
As above
 
5. Date of the transaction and date on which the threshold is crossed or reached (v):
 
18 June 2008
 
6. Date on which issued notified:
 
19 June 2008
 
7. Threshold(s) that is/are crossed or reached:
 
13%
8. Notified details
 
A: Voting rights attached to shares
 
Class/type of share if possible using the ISIN Code GB00B28XMY25
 
Situation Previous to the triggering transaction (vi) –
Number of Shares 1,477,000
Number of Voting Rights (viii) 1,477,000
 
Resulting situation after the triggering transaction (viii) –
Number of Shares 1,495,000
Number of Voting Rights – Direct (x) 1,495,000
Number of Voting Rights – Indirect (xi) N/A
% of voting rights – Direct 13.02%
% of voting rights – Indirect N/A
B: Financial Instruments
Resulting situation after the triggering transaction (xii)
 
Type of financial instrument N/A
 
Expiration date (xiii) N/A
 
Exercise/Conversion Period/Date (xiv) N/A
 
Number of voting rights that may be acquired if the
instrument is exercised/converted N/A
 
% of voting rights N/A
Total (A+B)
 
Number of voting rights 1,495,000
 
% of voting rights 13.02
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):
 
Shares are held in own name
 
Proxy Voting:
 
10. Name of the proxy holder: N/A
 
11. Number of voting rights proxy holder will cease to hold: N/A
 
12. Date on which proxy holder will cease to hold voting rights: N/A
 
13. Additional information: N/A
 
14. Contact name: N/A
 
15. Contact telephone number: N/A
 
 
For further information:
 
Percy Lomax
ReGen Therapeutics Plc
Tel: +44 (0) 207 153 4920
 
Roland Cornish / Felicity Geidt
Beaumont Cornish Limited
Tel: +44(0) 207 628 3396

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKCKDABKDCAD
Date   Source Headline
30th Mar 202112:30 pmRNSAccustem Update
30th Mar 20217:00 amRNSP2 Study in Moderate to Severe Covid-19 Patients
29th Mar 20211:02 pmRNSUpdated: Gabriele Cerrone, Bloomberg Interview
29th Mar 20217:00 amRNSChairman of Tiziana to give interview on Bloomberg
26th Feb 20217:00 amRNSTiziana Interview to Air on Bloomberg TV
16th Feb 20212:37 pmRNSTiziana at BIO CEO & Investor Digital Conference
5th Feb 20217:10 amRNSDirector/PDMR Shareholding
5th Feb 20217:00 amRNSAPPOINTMENT OF DIRECTOR
3rd Feb 20217:00 amRNSCEO exclusive interview to discuss COVID-19 Trial
2nd Feb 20214:41 pmRNSSecond Price Monitoring Extn
2nd Feb 20214:36 pmRNSPrice Monitoring Extension
2nd Feb 20219:05 amRNSSecond Price Monitoring Extn
2nd Feb 20219:00 amRNSPrice Monitoring Extension
2nd Feb 20217:00 amRNSPositive Data: Nasal Administration of Foralumab
27th Jan 20217:00 amRNSTiziana files F-3 Statement with U.S. SEC
26th Jan 20217:00 amRNSUpdated corporate presentation
20th Jan 202111:04 amRNSB. Riley Virtual Oncology Investor Conference
20th Jan 20217:00 amRNSAIM Delisting and Admission to the Main Market
13th Jan 20217:00 amRNSAppointment of Chief Medical Officer
11th Jan 20214:46 pmRNSTiziana at J.P. Morgan Healthcare Conference 2021
11th Jan 20212:48 pmRNSTiziana to Present at Biotech Showcase Digital
4th Jan 20219:05 amRNSSecond Price Monitoring Extn
4th Jan 20219:00 amRNSPrice Monitoring Extension
4th Jan 20217:00 amRNSCompletion of Foralumab Clinical Trial in Brazil
18th Dec 202011:13 amRNSPublication of Prospectus
17th Dec 20203:00 pmRNSNotification of Admission to the Main Market
10th Dec 20207:00 amRNSDirector/PDMR Shareholding
1st Dec 20207:00 amRNSTiziana Life Sciences to Host Investor Update Call
18th Nov 20202:00 pmRNSDirector/PDMR Shareholding
11th Nov 20207:00 amRNSPhase 1b/2 Clinical Trial - Crohn's Disease
9th Nov 20202:05 pmRNSSecond Price Monitoring Extn
9th Nov 20202:00 pmRNSPrice Monitoring Extension
2nd Nov 20209:05 amRNSSecond Price Monitoring Extn
2nd Nov 20209:00 amRNSPrice Monitoring Extension
2nd Nov 20207:00 amRNSInitiation of Clinical Trial for COVID-19 Patients
29th Oct 20207:00 amRNSExercise of Options, Issue of Equity, PDMR Dealing
29th Oct 20207:00 amRNSDemerger Update and Timetable Confirmation
28th Oct 20207:00 amRNSIssue of Equity on Exercise of Warrants
27th Oct 20204:00 pmRNSDemerger of StemPrintER
26th Oct 20207:00 amRNSExercise of Options, Issue of Equity, PDMR Dealing
22nd Oct 20204:36 pmRNSIssue of Equity on Exercise of Warrants
21st Oct 20207:00 amRNSExercise of Options, Issue of Equity, PDMR Dealing
20th Oct 20207:00 amRNSIssue of Equity on Exercise of Warrants
2nd Oct 202012:00 pmRNSResult of GM
30th Sep 20207:00 amRNSHalf-year Report
25th Sep 20204:40 pmRNSSecond Price Monitoring Extn
25th Sep 20204:35 pmRNSPrice Monitoring Extension
25th Sep 20207:00 amRNSInterview - Bloomberg International
21st Sep 20202:11 pmRNSPublication of Research Note
21st Sep 20207:00 amRNSIssue of Equity and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.